Depends on the partnering route taken as to what the funds from the upfront are used for. The way I understand it:
Option A = Out license to big pharma = sale of the AD214 asset with an upfront payment & contingent milestones = no further spend on AD214 for Adalta, can use the upfront to develop the pipeline of other drugs
Option B = JV Partner with Private equity = AD214 into SPV, JV partner pays Adalta for a portion of equity in SPV = in phase II either the costs are shared with the JV partner or the JV partner pays 100% (depending on the deal and how much equity is given away) with hope of selling for more (to big pharma) at some point
Depends on the partnering route taken as to what the funds from...
Add 1AD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.26M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.3¢ | 2.3¢ | $2.846K | 123.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 481618 | 2.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 93450 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.4¢ |
Change
0.000 ( 4.35 %) |
||||
| Open | High | Low | Volume | ||
| 2.3¢ | 2.4¢ | 2.3¢ | 23125 | ||
| Last updated 10.37am 10/05/2024 ? | |||||
| 1AD (ASX) Chart |